Pruritus is a common comorbid symptom of patients with chronic liver disease [6], which is of special interest because FXR agonists are a widely investigated and promising drug class for the treatment of NASH but are associated with drug-class-specific pruritogenic side effects that impair tolerability [5]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.